VOWST WAS STUDIED IN A RIGOROUS PHASE 3 CLINICAL DEVELOPMENT PROGRAM
VOWST PROVIDED SUPERIOR PREVENTION OF
C. DIFF
RECURRENCE VS. ANTIBIOTICS ALONE
Statistically significant reduction of C. diff recurrence at 8 weeks1,2*
- A Number Needed to Treat (NNT) of 4 to avoid 1 C. diff recurrence2
VOWST PROVIDED A DURABLE RESPONSE
AT 24 WEEKS1,3
Statistically significant reduction of
C. diff
recurrence compared to
antibiotics alone1,3†
* Calculated by the rate of C. diff recurrence, which was significantly lower in VOWST recipients compared to those receiving antibiotics alone—12% vs. 40%, respectively—a 0.32 relative risk (95% confidence interval, 0.18, 0.58; P <0.001).1,2
† Relative risk of 0.46 (95% CI, 0.30, 0.73).
ECOSPOR III was a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial evaluating C. diff recurrence at 8 weeks; secondary endpoints at 4, 12, 24 weeks. In the intent-to-treat population, participants received standard-of-care antibiotics (vancomycin/fidaxomicin) and laxative followed by VOWST or placebo. Those lost to follow-up, terminated prematurely, or died prior to end of study time interval counted as a recurrence. Data were rounded to the nearest whole number for presentation.
